Some syngeneic cancer cell models have also been reported in which the expression of Loxl2 has been genetically manipulated and the resulting cell lines orthotopically injected into immune-competent syngeneic mouse lines, providing valuable preclinical models. Here, LOXL2 is linked to cancer.